CytoImmune Therapeutics to Participate in the Cowen's 42nd Annual Health Care Conference MONROVIA, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based...

CytoImmune Therapeutics to Participate in the 2022 BIO CEO & Investor Conference and the SVB Leerink Global Healthcare Conference MONROVIA, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a clinical-stage cell therapy company that is developing a novel class of tumor-reactive engineered natural killer...

CytoImmune Therapeutics Announces Publication Demonstrating Platelet-Derived Growth Factor D Signaling Activates Natural Killer (NK) Cells and Enhances NK Cell Survival TOA BAJA, Puerto Rico, Jan. 25, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of natural killer (NK) cell-based cancer...

CytoImmune Appoints Distinguished Cell Therapy and Chemistry, Manufacturing and Controls Expert as Puerto Rico-Based Chief Operating Officer TOA BAJA, Puerto Rico, Dec. 14, 2021 (GLOBE NEWSWIRE) --  CytoImmune Therapeutics, a clinical-stage cell immunotherapy company developing novel natural killer (NK) cell therapies to fight cancer,...

CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a privately-held cell therapy company focused on developing natural killer (NK) immune cells to fight cancer, announces the...